-
Shanghai Escugen Partners with InxMed for Global Development Rights to EZWi-Fit Platform
•
Shanghai Escugen has entered into a partnership with InxMed (Nanjing) Co., Ltd, granting the Chinese firm non-exclusive global rights to Escugen’s EZWi-Fit linker-payload platform for the development of next-generation tumor-associated antigen (TAA)-targeting antibody drug conjugates (ADCs). Under the terms of the license agreement, InxMed is authorized to utilize the EZWi-Fit…
-
InxMed Presents Positive Data for FAK Inhibitor Ifebemtinib at ESMO 2023
•
China-based firm InxMed (Nanjing) Co., Ltd has updated two clinical studies for its first-in-class small-molecule FAK inhibitor ifebemtinib (IN10018) at the European Society for Medical Oncology (ESMO) Congress 2023. The studies evaluated the drug’s efficacy and safety in treating platinum-resistant recurrent ovarian cancer and advanced triple negative breast cancer. Phase…
